Correlation Between Lumos Pharma and Virpax Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Lumos Pharma and Virpax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lumos Pharma and Virpax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lumos Pharma and Virpax Pharmaceuticals, you can compare the effects of market volatilities on Lumos Pharma and Virpax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lumos Pharma with a short position of Virpax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lumos Pharma and Virpax Pharmaceuticals.

Diversification Opportunities for Lumos Pharma and Virpax Pharmaceuticals

-0.25

Correlation Coefficient

Lumos Pharma  Virpax Pharmaceuticals

Very good diversification

The 3 months correlation between Lumos and Virpax is -0.25. Overlapping area represents the amount of risk that can be diversified away by holding Lumos Pharma and Virpax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virpax Pharmaceuticals and Lumos Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lumos Pharma are associated (or correlated) with Virpax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virpax Pharmaceuticals has no effect on the direction of Lumos Pharma i.e., Lumos Pharma and Virpax Pharmaceuticals go up and down completely randomly.

Pair Corralation between Lumos Pharma and Virpax Pharmaceuticals

Given the investment horizon of 90 days Lumos Pharma is expected to generate 0.37 times more return on investment than Virpax Pharmaceuticals. However, Lumos Pharma is 2.74 times less risky than Virpax Pharmaceuticals. It trades about 0.05 of its potential returns per unit of risk. Virpax Pharmaceuticals is currently generating about -0.02 per unit of risk. If you would invest  306.00  in Lumos Pharma on September 15, 2024 and sell it today you would earn a total of  128.00  from holding Lumos Pharma or generate 41.83% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	99.63%
Values	Daily Returns

Lumos Pharma  vs.  Virpax Pharmaceuticals

Lumos Pharma

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Lumos Pharma are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent primary indicators, Lumos Pharma displayed solid returns over the last few months and may actually be approaching a breakup point.

Virpax Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Lumos Pharma and Virpax Pharmaceuticals

The main advantage of trading using opposite Lumos Pharma and Virpax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lumos Pharma position performs unexpectedly, Virpax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virpax Pharmaceuticals will offset losses from the drop in Virpax Pharmaceuticals' long position.

The idea behind Lumos Pharma and Virpax Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.